| Citation: |
GAO Guanlun, ZHOU Xuan, XU Na, LIU Xiaoli, WEI Ting, LI Qingshan. Clinical Characteristics of Chronic Myeloid Leukemia Patients with Deletion and Non-deletion of ASS Gene on Derivative Chromosome 9[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 283-287. DOI: 10.3971/j.issn.1000-8578.2023.22.0701
|
To investigate the clinical characteristics of patients with chronic myeloid leukemia (CML) in chronic phase with deletion and non-deletion of the argininosuccinate synthesis gene (ASS gene) on the derivative chromosome 9.
The clinical data of patients with CML initially treated with imatinib and BCR/ABL1/ASS1 3-color fusion probe to detect ASS gene deletion were analyzed. The patients were divided into deletion group (n=27) and non-deletion group (n=92). Clinical characteristics, treatment effects, and prognosis were analyzed.
The average age of 119 patients was 37.22±12.72 years old. The sokal score differed between the deletion and non-deletion groups (χ2=4.304, P=0.038). No statistically significant difference in other general characteristics was found (P > 0.05). The 3-month CCyR rate, 6-month CCyR rate, and BCR-ABLIS≤ 1% rate in the deletion group were lower than those in the non-deletion group (P < 0.05). The median follow-up of 119 patients was 35.0 (3.0-60.0) months. The PFS in the deletion group was lower than that in the non-deletion group (χ2=4.293, P=0.038). Overall survival was not significantly different between the two groups (χ2=0.008, P=0.931).
The deletion of the ASS gene in patients with chronic CML is related to the poor efficacy of imatinib treatment, poor prognosis, and high risk of disease progression.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring[J]. Am J Hematol, 2020, 95(6): 691-709. doi: 10.1002/ajh.25792
|
| [2] |
Chandran RK, Geetha N, Sakthivel KM, et al. Prognostic Implications of Derivative Chromosome 9 Deletions in Patients with Advanced-Stage Chronic Myelogenous Leukemia[J]. J Environ Pathol Toxicol Oncol, 2018, 37(2): 117-126. doi: 10.1615/JEnvironPatholToxicolOncol.2018026023
|
| [3] |
Asnafi AA, Deris Zayeri Z, Shahrabi S, et al. Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches[J]. J Cell Physiol, 2019, 234(5): 5798-5806. doi: 10.1002/jcp.27505
|
| [4] |
Li JY, Xu W, Wu W, et al. The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in the chronic phase[J]. Onkologie, 2008, 31(11): 585-589.
|
| [5] |
中华医学会血液学分会. 中国慢性髓性白血病诊断与治疗指南(2016年版)[J]. 中华血液学杂志, 2016, 37(8): 633-639. https://xuewen.cnki.net/CCND-YIYA201610190061.html
Chinese Society of Hematology, Chinese Medical Association. The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2016 edition)[J]. Zhonghua Xue Ye Xue Za Zhi, 2016, 37(8): 633-639. https://xuewen.cnki.net/CCND-YIYA201610190061.html
|
| [6] |
Deininger MW, Shah NP, Altman JK, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2020, 18(10): 1385-1415. doi: 10.6004/jnccn.2020.0047
|
| [7] |
Zhou T, Medeiros LJ, Hu S. Chronic Myeloid Leukemia: Beyond BCR-ABL1[J]. Curr Hematol Malig Rep, 2018, 13(6): 435-445. doi: 10.1007/s11899-018-0474-6
|
| [8] |
Zhang H, Liu M, Wang X, et al. Genomic Copy Number Variants in CML Patients With the Philadelphia Chromosome (Ph+): AnUpdate[J]. Front Genet, 2021, 12: 697009. doi: 10.3389/fgene.2021.697009
|
| [9] |
张朕豪, 王艳芳, 王淼, 等. 应用三色双融合探针检测BCR-ABL融合基因及ASS1基因缺失[J]. 中国实验血液学杂志, 2020, 28(4): 1115-1122. doi: 10.19746/j.cnki.issn1009-2137.2020.04.006
Zhang ZH, Wang YF, Wang M, et al. [Detection of BCR/ABL Fusion Gene and ASS1 Gene Deletion by Using Tricolor Dual-fusion Probe[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2020, 28(4): 1115-1122. doi: 10.19746/j.cnki.issn1009-2137.2020.04.006
|
| [10] |
Fourouclas N, Campbell PJ, Bench AJ, et al. Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia[J]. Haematologica, 2006, 91(7): 952-955
|
| [11] |
Egan D, Radich J. Making the diagnosis, the tools, and risk stratification: More than just BCR-ABL[J]. Best Pract Res Clin Haematol, 2016, 29(3): 252-263. doi: 10.1016/j.beha.2016.10.015
|
| [12] |
Fernandes A, Shanmuganathan N, Branford S. Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia[J]. Cancers (Basel), 2022, 14(3): 620. doi: 10.3390/cancers14030620
|
| [13] |
Hochhaus A, Baccarani M, Silver RT, et al. European leukemianet 2020 recommendations for treating chronic myeloid leukemia[J]. Leukemia, 2020, 34: 966-984. doi: 10.1038/s41375-020-0776-2
|
| [14] |
Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia[J]. N Engl J Med, 2017, 376(10): 917-927. doi: 10.1056/NEJMoa1609324
|
| [15] |
Gorusu M, Benn P, Li Z, et al. On the genesis and prognosis of variant translocations in chronic myeloid leukemia[J]. Cancer Genet Cytogenet, 2007, 173(2): 97-106. doi: 10.1016/j.cancergencyto.2006.10.006
|
| [16] |
董洁, 李薇, 白晶, 等. 9号衍生染色体在慢性粒细胞白血病预后评估中的意义[J]. 吉林大学学报(医学版), 2016, 42(2): 301-305. https://www.cnki.com.cn/Article/CJFDTOTAL-BQEB201602021.htm
Dong J, Li W, Bai J, et al. Significance of derivative chromosome 9 in evaluation on prognosis of chronic myeloid leukemia[J]. Jilin Da Xue Xue Bao(Yi Xue Ban), 2016, 42(2): 301-305. https://www.cnki.com.cn/Article/CJFDTOTAL-BQEB201602021.htm
|
| [17] |
Kim DH, Popradi G, Sriharsha L, et al. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia[J]. Cancer, 2008, 113(4): 772-781. doi: 10.1002/cncr.23607
|
| [18] |
Švabek ŽT, Josipović M, Horvat I, et al. The incidence of atypical patterns of BCR-ABL1 rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML)[J]. Blood Res, 2018, 53(2): 152-159. doi: 10.5045/br.2018.53.2.152
|
| [19] |
Quintás-Cardama A, Kantarjian H, Shan J, et al. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib[J]. Cancer, 2011, 117(22): 5085-5093. doi: 10.1002/cncr.26147
|
| [20] |
Bennour A, Ouahchi I, Ben Youssef Y, et al. Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients[J]. Med Oncol, 2012, 29(2): 1151-1160. doi: 10.1007/s12032-011-9918-8
|
| [21] |
Jiang Y, Zhang J, Guo D, et al. Entire ABL1 Gene Deletion Without BCR/ABL1 Rearrangement in a Female Patient with B-Cell Precursor Acute Lymphoblastic Leukemia[J]. Onco Targets Ther, 2020, 13: 783-790. doi: 10.2147/OTT.S238336
|
| [22] |
Bennour A, Sennana H, Laatiri MA, et al. Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9[J]. Cancer Genet Cytogenet, 2009, 194(1): 30-37. doi: 10.1016/j.cancergencyto.2009.05.010
|
| [23] |
Kreil S, Pfirrmann M, Haferlach C, et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia[J]. Blood, 2007, 110(4): 283-1290.
|
| [24] |
李珍, 张龑莉, 赵慧芳, 等. 伊马替尼联合三氧化二砷治疗伴有ASS基因缺失的Ph+慢性粒细胞白血病的临床研究[J]. 中国实用医刊, 2019, 46(11): 97-99. https://www.cnki.com.cn/Article/CJFDTOTAL-HBZY201812008.htm
Li Z, Zhang YL, Zhao HF, et al. Effects of imatinib combined arsenic trioxide on Ph+chronic myeloid leukemia patients lacking of ASS genes[J]. Zhongguo Shi Yong Yi Kan, 2019, 46(11): 97-99. https://www.cnki.com.cn/Article/CJFDTOTAL-HBZY201812008.htm
|
| [1] | XIA Bingtian, HE Fang, SONG Bingxin, WANG Lili, ZHU Tingjun, JIA Yongqing, HU Huixian. Inhibition and Mechanism of Imatinib on A549 Xenograft Tumor in Nude Mice via PDGF/PDGFR Pathway[J]. Cancer Research on Prevention and Treatment, 2023, 50(9): 854-859. DOI: 10.3971/j.issn.1000-8578.2023.23.0228 |
| [2] | DING Pingan, YANG Peigang, TIAN Yuan, LIN Yecheng, GUO Honghai, LIU Yang, ZHANG Zhidong, WANG Dong, LI Yong, ZHAO Qun. Clinicopathological Characteristics and Prognosis of Borrmann Type Ⅳ Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 261-267. DOI: 10.3971/j.issn.1000-8578.2021.20.0770 |
| [3] | DONG Fei, PANG Meng, ZHENG Dong, ZHEN Jingfei, JING Hongmei. Clinical Characteristics and Prognosis of Primary Thyroid Lymphoma Patients[J]. Cancer Research on Prevention and Treatment, 2019, 46(6): 515-518. DOI: 10.3971/j.issn.1000-8578.2019.18.1561 |
| [4] | ZHANG Wenlong, ZHANG Panpan, SI Jiahui, MA Yuanyuan, YANG Yue. HLA-G Expression in Lung Adenocarcinoma Tissues and Its Relationship with Prognosis[J]. Cancer Research on Prevention and Treatment, 2018, 45(8): 566-570. DOI: 10.3971/j.issn.1000-8578.2018.17.1594 |
| [5] | JIN Long, FU Shenbo, YU Jiao. Effect of NLR and PLR from Pre-treatment on Prognosis of Nasopharyngeal Carcinoma Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(7): 476-480. DOI: 10.3971/j.issn.1000-8578.2017.16.1536 |
| [6] | LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007 |
| [7] | HE Lang, HOU Mei, LI Chang-lin, LI Guang-ming. Unsuitable Marker for PKCα to Predict Prognosis of Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(01): 66-69. DOI: 10.3971/j.issn.1000-8578.2010.01.018 |
| [8] | ZHAO Lin, WAN G Yu-zhou, BAI Chun-mei, CHEN Shu-chang. An Analysis of 91 Cases of Gastrointestinal Stromal Tumors[J]. Cancer Research on Prevention and Treatment, 2007, 34(01): 59-62. DOI: 10.3971/j.issn.1000-8578.3423 |
| [9] | Chen Mu, Wang Zhong-qiang. The relation of erythroblast in peripheral blood of acute leukemia to rosponse for treatment and prognosis[J]. Cancer Research on Prevention and Treatment, 1996, 23(6): 332-334. |
| [10] | Zhang Jianbin, . Pathological Morphology and Prognosis on 29 Cases of Medullary Thyroid Carcinoma[J]. Cancer Research on Prevention and Treatment, 1994, 21(3): 150-151. |
Figures(1) / Tables(2)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: